Prospective,Randomized,Multi-Center Feasibility Trial of rhPDGF-BB versus Autologous Bone Graft in a Foot and Ankle Fusion Model

Abstract

Background:

The increased morbidity and surgical time associated with harvesting autologous bone graft (ABG) have encouraged surgeons to develop synthetic orthobiologic alternatives. The recombinant form of platelet-derived growth factor (rhPDGF-BB), an angiogenic, mitogenic, and chemotactic cytokine, has been shown to significantly enhance bone formation in human periodontal osseous defects when combined with a tricalcium phosphate carrier (β-TCP). The purpose of this prospective, controlled, randomized, multi-center feasibility clinical trial was to compare the safety and efficacy of this biosynthetic bone graft substitute (Augment™ Bone Graft) to ABG during ankle and hindfoot fusion.

Materials and Methods:

Twenty adult subjects requiring ankle or hindfoot fusion from three U.S. centers were enrolled and randomized in a 2:1 ratio to receive Augment™ or ABG, respectively. Surgical approach and fixation techniques were standardized, and minimum followup was 9 months. The primary endpoint was radiographic osseous union, evaluated by a blinded independent radiologist. Secondary endpoints included assessment of clinical success, union rate by serial computed tomography (CT) examination, time to full weightbearing, AOFAS Ankle-Hindfoot Score (AOFAS), Foot Function Index (FFI), Short Form-12 (SF-12), and Visual Analog pain assessment Scale (Pain VAS).

Results:

At 36 weeks, 77% (10/13) of the Augment™ and 50% (3/6) of the ABG patients were fused based on radiographic criteria. There were two nonunions in the Augment™ group (9%, 2/14). Healing rates based on 12 week CT scanning (50% osseous bridging) were 69% (9/13) in the Augment™ and 60% (3/5) in the ABG groups, respectively. All functional outcome measures (FFI, AOFAS, SF-12), as well as the VAS pain scores, improved in both groups over time. Surgical procedure times lasted an average 26 minutes longer for the ABG as compared to the Augment™ populations. There were no device related serious adverse events in this study.

Conclusion:

Based on the available data, the rate of radiographic union, time to full weightbearing, and outcomes scores between the Augment™ and ABG subjects appear comparable. Augment™ may represent a safe and efficacious treatment alternative to ABG during foot and ankle arthrodesis.

Level of Evidence:

Keywords

Ankle and Hindfoot fusion Autologous Bone Graft Recombinant Platelet Derived Growth Factor Biosynthetic Bone Graft Substitute

Get full access to this article

View all access options for this article.

References

Al-Zube

Breitbart

O'Connor

: Recombinant Human Platelet-Derived Growth Factor BB (rhPDGF-BB) and Beta- Al-Zube, L; Breitbart, EA; O'Connor, JP; et al.: Recombinant Tricalcium Phosphate/Collagen Matrix Enhance Fracture Healing in a Diabetic Rat Model. J Ortho Res. 27(8):1074–81, 2009. https://dx-doi-org.web.bisu.edu.cn/10.1002/jor.20842.

Burkus

Gornet

Dickman

Zdeblick

: Anterior Lumbar Interbody Fusion Using rhBMP-2 with Tapered Interbody Cages. J Spinal Disord Tech. 15:337–349, 2002.

Coughlin

Grimes

Traughber

Jones

: Comparison of Radiographs and CT Scans in the Prospective Evaluation of the Fusion of Hindfoot Arthrodesis. Foot and Ankle Int. 27(10):780–787, 2006.

Daniels

DiGiovanni

Lau

Wing

Younger

: Prospective Clinical Pilot Trial in a Single Cohort Group of rhPDGF in Foot Arthrodeses. Foot Ankle Int. 31(6):473–479, 2010. https://dx-doi-org.web.bisu.edu.cn/10.3113/FAI.2010.0473.

Dorsey

: Correlation of Arthrodesis Stability with Degree of Joint Fusion on MDCT. Am J Rad. 192:496–499, 2009.

Easley

Trnka

Schon

Myerson

: Isolated Subtalar Arthrodesis. JBJS Am. 82-A(5): 613–624, 2000.

Foot and Ankle. In: The OrthoFact Book™: U.S. 5th Edition. Chagrin Falls, OH: Knowledge Enterprises; 2005 April.

Frey

Halikus

Vu-Rose

Ebramzadeh

: A Review of Ankle Arthrodesis: Predisposing Factors to Nonunion. Foot Ankle Int. 5(11):581–584, 1994.

Friedlaender

Perry

Cole

: Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in the Treatment of Tibial Nonunions. JBJS Am. 83 Suppl 1:S151–158, 2001.

10.

Gazdag

Lane

Glaser

Forster

: Alternatives to Autogenous Bone Graft: Efficacy and Indications. JAAOS. 3(1):1–8, 1995.

11.

Govender

Csimma

Genant

: BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients. JBJS Am. 84:2123–2134, 2002.

12.

Hollinger

Onikepe

MacKrell

: Accelerated Fracture Healing in the Geriatric, Osteoporotic Rat with Recombinant Human Platelet-Derived Growth Factor-BB and an Injectable Beta-Tricalcium Phosphate/Collagen Matrix. Journal of Orthopaedic Research 26(1):83–90, 2008. https://dx-doi-org.web.bisu.edu.cn/10.1002/jor.20453.

13.

Howell

Fiorellini

Paquette

: A Phase I/II Clinical Trial to Evaluate a Combination of Recombinant Human Platelet-derived Growth Factor-BB and Recombinant Human Insulinlike Growth Factor-I in Subjects with Periodontal Disease. J Periodontol. 68:1186–1193, 1997.

14.

Johnsson

Stromqvist

Aspenberg

: Randomized Radiostereometric Study Comparing Osteogenic Protein-1 (BMP-7) and Autograft Bone in Human Non- Instrumented Posterolateral Lumbar Fusion. Spine. 27:2654–2661, 2002. https://dx-doi-org.web.bisu.edu.cn/10.1097/00007632-200212010-00004.

15.

Kohler

Lipton

: Platelets as a Source of Fibroblast Growth-Promoting Activity. Exp. Cell Res. 87:197–301, 1974. https://dx-doi-org.web.bisu.edu.cn/10.1016/0014-4827(74)90484-4.

16.

Lynch

Williams

Polson

: A Combination of Platelet-Derived Growth Factor and Insulin-like Growth Factor Enhances Periodontal Regeneration. J Clin Periodontol. 16:545–554, 1989. https://dx-doi-org.web.bisu.edu.cn/10.1111/j.1600-051X.1989.tb02334.x.

17.

Moore

Ehrlich

McAllister

: Recombinant Human Platelet-Derived Growth Factor-BB Augmentation of New-Bone Formation in a Rat Model of Distraction Osteogenesis. JBJS Am. 91:1973–1984, 2009.

18.

Nevins

Giannobile

McGuire

: Platelet-Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain: Results of a Large Multicenter Randomized Controlled Trial. J Periodontol. 76(12):2205–2215, 2005. https://dx-doi-org.web.bisu.edu.cn/10.1902/jop.2005.76.12.2205.

19.

Praemer

Furner

Rice

: Musculoskeletal Conditions in the United States. American Academy of Orthopaedic Surgeons. 1999:85–124.

20.

Ranly

Lohmann

Andreacchio

Boyan

Schwartz

: Platelet-Rich Plasma Inhibits Demineralized Bone Matrix-Induced Bone Formation in Nude Mice. JBJS Am. 89(1):139–147, 2007.

21.

Ranly

McMillan

Keller

: Platelet-Derived Growth Factor Inhibits Demineralized Bone Matrix-Induced Intramuscular Cartilage and Bone Formation. A Study of Immunocompromised Mice. JBJS Am. 87(9):2052–2064, 2005.

22.

Ross

Glomset

Kariya

Harker

: A Platelet-Dependent Serum Factor that Stimulates the Proliferation of Arterial Smooth Muscle Cells in Vitro. Proc. Nat. Acad. Sci. 71:1207–1210, 1974. https://dx-doi-org.web.bisu.edu.cn/10.1073/pnas.71.4.1207.

23.

Ross

Vogel

: The Platelet-Derived Growth Factor. Cell. 14:203–210, 1978 June.

24.

Ross

Raines

Bowen-Pope

: The Biology of Platelet-Derived Growth Factor. Cell. 46:155–169, 1986 July.

25.

St. John

Vaccaro

Sah

: Physical and Monetary Costs Associated with Autogenous Bone Graft Harvesting. Am J Ortho. 18–23, 2003 Jan.

26.

Summers

Eisenstein

: Donor Site Pain from the Ilium. JBJS Br. 71:677–680, 1989.

27.

Younger

Chapman

: Morbidity at Bone Graft Donor Sites. J Orthop Trauma. 3:192–195, 1989. https://dx-doi-org.web.bisu.edu.cn/10.1097/00005131-198909000-00002.

28.

Zelen

: The Randomization and Stratification of Patients to Clinical Trials. J Chronic Disease. 27(7–8):365–375, 1974. https://dx-doi-org.web.bisu.edu.cn/10.1016/0021-9681(74)90015-0.